Requests that the FDA remove from the market the injectable contraceptive Depot Medroxyprogesterone Acetate (DMPA; Depo Provera) based on conclusive evidence that it uniquely facilitates the transmission of HIV from men to women and has other known risks. Numerous alternatives are available. | Federal Regulations · Congress.wiki